CHOLINE-2 - Donepezil Versus Non-drug Treatment in Alzheimer's Disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515038-34-00

Acronym

APHP201183

Enrollment

240

Registered

2024-10-24

Start date

2022-02-10

Completion date

Unknown

Last updated

2024-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease

Brief summary

Difference in MMSE score between inclusion and 6 months, in the arm treated with donepezil and the usual course of care arm.

Detailed description

Difference at 6 months in scores, ADAS-Cog, CDR, ADCS-ADL, quality of life, ZARIT.

Interventions

DRUGDONEPEZIL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Difference in MMSE score between inclusion and 6 months, in the arm treated with donepezil and the usual course of care arm.	—

Secondary

Measure	Time frame
Difference at 6 months in scores, ADAS-Cog, CDR, ADCS-ADL, quality of life, ZARIT.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026